RA Capital Management

Type

Venture Capital

Status

Active

Location

Boston, United States

Total investments

411

Average round size

86M

Portfolio companies

296

Rounds per year

17.87

Lead investments

71

Follow on index

0.28

Exits

123

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

RA Capital Management appeared to be the VC, which was created in 2001. The leading representative office of defined VC is situated in the Boston. The venture was found in North America in United States.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the RA Capital Management, startups are often financed by OrbiMed, F-Prime Capital, Flybridge Capital Partners. The meaningful sponsors for the fund in investment in the same round are Wellington Management, Longitude Capital, Deerfield. In the next rounds fund is usually obtained by OrbiMed, Cormorant Asset Management, Polaris Partners.

Opposing the other organizations, this RA Capital Management works on 23 percentage points more the average amount of lead investments. The fund is generally included in 7-12 deals every year. The real fund results show that this VC is 4 percentage points more often commits exit comparing to other companies. The average startup value when the investment from RA Capital Management is more than 1 billion dollars. The increased amount of exits for fund were in 2015. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 50 - 100 millions dollars.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline AveXis, Moderna Therapeutics, Intarcia Therapeutics Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Health Diagnostics.

This organization was formed by Richard Aldrich. We also calculated 4 valuable employees in our database.

Show more

Investor highlights

Industry focus
Healthcare
Stage focus
SeedSeries DSeries CSeries ASeries B
Check size
600K — 75M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 461000000
Fund raised date
2020-10-22

Analytics

Total investments
411
Lead investments
71
Exits
123
Rounds per year
17.87
Follow on index
0.28
Investments by industry
  • Biotechnology (352)
  • Health Care (225)
  • Therapeutics (150)
  • Pharmaceutical (114)
  • Medical (108)
  • Show 54 more
Investments by region
  • United States (333)
  • United Kingdom (14)
  • China (7)
  • Canada (13)
  • Denmark (7)
  • Show 10 more
Peak activity year
2021
Number of Unicorns
8
Number of Decacorns
8
Number of Minotaurs
16

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
89M
Group Appearance index
0.95
Avg. company exit year
7
Avg. multiplicator
2.81
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Bright Peak Therapeutics 11 Jun 2024 Biotechnology, Therapeutics Late Stage Venture 90M Switzerland, Basel-City, Basel
TORL BioTherapeutics 10 Apr 2024 Biotechnology, Biopharma, Clinical Trials Early Stage Venture 158M United States, California, Los Angeles

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.